滋水清肝汤联合度洛西汀治疗抑郁症50例

Clinical Efficacy of WNLC Decoction Combined with Duloxetine in Treating Depression in 50 Cases

目的观察滋水清肝汤联合度洛西汀治疗抑郁症的疗效及安全性。方法将100例抑郁症患者随机分为试验组和对照组,各50例。对照组采用度洛西汀治疗,试验组采用滋水清肝汤联合度洛西汀治疗,于治疗前和治疗后第2,4,8周分别采用汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表(CGI)评价疗效,以HAMD-17减分率为主要疗效判定指标,同时观察并记录试验期间发生的不良反应。结果试验组和对照组总有效率分别为88.00%和74.00%,差异无统计学意义,但试验组和对照组的HAMD-17评分在治疗第2,4,8周时差异均有统计学意义(P<0.05),试验组平均评分均低于对照组(P<0.05);试验组的不良反应发生率为38.00%,显著低于对照组的64.00%(P<0.05)。结论滋水清肝汤联合度洛西汀治疗抑郁症可提高临床疗效和降低不良反应发生率,值得临床推广。

Objective To observe the efficacy and safety of duloxetine combined with Water- Nourishing and Liver-Clearing （WNLC） Decoction in treating depression. Methods By using the randomized, parallel- controlled method, 100 patients with depression were randomized to the experimental group and the control group,50 cases in each group. The control group was treated by duloxetine,while the treatment group adopted duloxetine combined with WNLC decoction. The efficacy before and at 2,4,8 weeks alter treatment was evaluated by the Hamilton Depression Scale （HAMD-17）,the Hamilton Anxiety Scale（HAMA） and the Clinical Global Impression Scale （CGI）,and the HAMD- 17 reductive ratio was taken as the main effect evaluation index. At the same time the adverse events occurred during the experimental period were observed and recorded. Results The total effective rates of the experimental group and the control group were 88.00% and 74. 00% without statistically significant difference;but the difference in the overall situation of the effects had statistical significance;the HAMD- 17 scores at 2,4,8 weeks of treatment in the experimental group and the control group had statistically significant difference（P 〈 0. 05）;the occurrence rate of adverse reactions in the experimental group was 38.00% ,which was significantly lower than 54. 00% in the control group（P 〈 0.05）. Conclusion WNLC Decoction combined with duloxetine in the treatment of depression is conducive to increase the clinical effect and reduce the occurrence rate of adverse reactlons,which is worthy of clinical promotion.